From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: SEED

Search articles by EPIC code
EPIC SEED
views

Seed Innovations – Ed McDermott Bullish but am I losing faith?

Seed Innovations (SEED) was my exposure to cannabis and a jolly disastrous investment it has been. At 2.6p I am almost 80% out of the money. My feeling is that the cannabis bubble has burst and yesterday’s comment on CBD HERE has to be bad news. I cant bring myself to cut the loss although maybe I should.  But of the NAV is 8p as Ed Claims maybe I should hang on? A couple of weeks ago I exchanged emails with Seed boss Ed McDermott asking him if he was alright?

EPIC SEED
views

Seed Innovations – investee company updates and still other IPO potential: BUY

Seed Innovations (SEED) is pleased to note that the company in which it holds 7,324,796 shares, Little Green Pharma (ASX:LGP), has announced its largest single-strain offtake quantity contract to date, with a minimum take or pay commitment of $7.5 million over 30 months." This follows the company in which it holds 4,427,609 shares, Yooma Wellness (CSE & AQSE - YOOM), announcing that its fourth quarter saw revenue of US$5.3 million, exceeding previous forecasts”.

EPIC SEED
views

Seed Innovations – a buy?

FastForward Innovations - now Seed Innovations (SEED) - was a recommendation last year on the N50 website which also features writers here Tom Winnifrith and Steve Moore. That was at a 6.2p offer price, noting the discount to NAV looked severe and looking for operational progress and increased interest particularly in the health area to propel NAV forward again. Little more than two months later the shares had already reached 12p to sell despite the company then stating “it is naturally a more challenging market for fundraising, which could delay the roll-out of future growth plans”. We banked gains, but there has been operational progress, though the shares are currently available at an 8.4p offer price.

Page 1 of 1 (10 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments